The University of Chicago Header Logo

Connection

Richard A. Larson to United States

This is a "connection" page, showing publications Richard A. Larson has written about United States.
Connection Strength

0.359
  1. Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU. Ann Hematol. 2015 Apr; 94 Suppl 2:S249-57.
    View in: PubMed
    Score: 0.051
  2. Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Adv. 2024 01 09; 8(1):164-171.
    View in: PubMed
    Score: 0.024
  3. The U.S. trials in adult acute lymphoblastic leukemia. Ann Hematol. 2004; 83 Suppl 1:S127-8.
    View in: PubMed
    Score: 0.023
  4. Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia. Blood Adv. 2022 07 26; 6(14):4085-4092.
    View in: PubMed
    Score: 0.021
  5. Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention. J Clin Oncol. 2022 11 10; 40(32):3709-3718.
    View in: PubMed
    Score: 0.021
  6. Recent clinical trials in acute lymphocytic leukemia by the Cancer and Leukemia Group B. Hematol Oncol Clin North Am. 2000 Dec; 14(6):1367-79, x.
    View in: PubMed
    Score: 0.019
  7. Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019 11; 25(11):2113-2123.
    View in: PubMed
    Score: 0.017
  8. Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. Leukemia. 2019 11; 33(11):2599-2609.
    View in: PubMed
    Score: 0.017
  9. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. Blood Adv. 2018 02 27; 2(4):444-453.
    View in: PubMed
    Score: 0.016
  10. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States. J Natl Cancer Inst. 2016 Jul; 108(7).
    View in: PubMed
    Score: 0.014
  11. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015 Aug; 90(8):996-1000.
    View in: PubMed
    Score: 0.013
  12. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015 Jan; 16(1):57-66.
    View in: PubMed
    Score: 0.013
  13. Current practices in the management of chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Feb; 13(1):48-54.
    View in: PubMed
    Score: 0.011
  14. Gemtuzumab ozogamicin: time to resurrect? J Clin Oncol. 2012 Nov 10; 30(32):3921-3.
    View in: PubMed
    Score: 0.011
  15. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. J Clin Oncol. 2012 Sep 01; 30(25):3109-18.
    View in: PubMed
    Score: 0.011
  16. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011 Sep; 12(9):841-51.
    View in: PubMed
    Score: 0.010
  17. Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997. Blood. 2011 Sep 29; 118(13):3525-7.
    View in: PubMed
    Score: 0.010
  18. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2011 Apr 01; 29(10):1373-81.
    View in: PubMed
    Score: 0.010
  19. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol. 2011 Apr 01; 29(10):1349-55.
    View in: PubMed
    Score: 0.010
  20. Therapy for acute myeloid leukemia and acute lymphoblastic leukemia in adults. Curr Opin Oncol. 1991 Feb; 3(1):30-8.
    View in: PubMed
    Score: 0.010
  21. End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood. 2007 Mar 01; 109(5):1810-6.
    View in: PubMed
    Score: 0.007
  22. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol. 2004 Mar 15; 22(6):1087-94.
    View in: PubMed
    Score: 0.006
  23. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003 Dec 15; 21(24):4642-9.
    View in: PubMed
    Score: 0.006
  24. Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. J Clin Oncol. 2001 Aug 15; 19(16):3611-21.
    View in: PubMed
    Score: 0.005
  25. A comparison study of chest tube thoracostomy: air medical crew and in-hospital trauma service. Air Med J. 1993 Jul; 12(7):227-9.
    View in: PubMed
    Score: 0.003
  26. Protooncogene expression and the clinical characteristics of acute nonlymphocytic leukemia: A Leukemia Intergroup pilot study. Blood. 1989 Jan; 73(1):255-62.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.